Table 1 Patient characteristics at enrollment by molecular subtype
|  | Subtype 1 (N = 105) | Subtype 2 (N = 127) | p-value+ |
|---|---|---|---|
Age | 70.08 (8.07) | 69.33 (7.62) | 0.31 |
Sex | Â | Â | 0.16 |
 M | 83 (79.1%) | 89 (70.1%) |  |
 F | 22 (21.0%) | 38 (30.0%) |  |
Ever smoker | Â | Â | 0.59 |
 Y | 73 (69.5%) | 83 (65.4%) |  |
 N | 32 (30.5%) | 44 (34.7%) |  |
History of coronary artery disease (including prior MI)* | Â | Â | 1.0 |
 Y | 33 (31.4%) | 39 (31.0%) |  |
 N | 72 (68.6%) | 87 (69.1%) |  |
History of COPD* | Â | Â | 1.0 |
 Y | 19 (18.1%) | 22 (17.5%) |  |
 N | 86 (81.9%) | 104 (82.5%) |  |
History of diabetes* | Â | Â | 0.18 |
 Y | 24 (22.9%) | 19 (15.1%) |  |
 N | 81 (77.1%) | 107 (84.9%) |  |
Antifibrotic treatment | Â | Â | 0.07 |
 Nintedanib | 24 (22.9%) | 18 (14.17%) |  |
 Pirfenidone | 41 (38.1%) | 43 (33.86%) |  |
 Neither | 40 (39.1%) | 66 (52.0%) |  |
DLCO % predicted | 38.31 (12.46) | 43.09 (14.69) | 0.01 |
FVC % predicted | 67.89 (15.18) | 73.82 (17.72) | 0.02 |
FEV1% predicted | 76.09 (16.11) | 81.03 (20.00) | 0.12 |
CPI [34] | 55.77 (9.93) | 51.21 (11.49) | 0.01 |
Diagnostic category [40] | Â | Â | 0.41 |
 Definite IPF | 77 (73.3%) | 95 (74.8%) |  |
 Probable IPF | 22 (21.0%) | 29 (22.8%) |  |
 Possible IPF | 6 (5.7%) | 3 (2.4%) |  |
GAP stage [39] | Â | Â | 0.15 |
 1 | 22 (21.0%) | 40 (31.5%) |  |
 2 | 64 (61.0%) | 71 (55.9%) |  |
 3 | 19 (18.1%) | 16 (12.6%) |  |